On Nov 14, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $150 to $185.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $132 to $176.
Goldman Sachs analyst Matthew Sykes maintains with a buy rating, and adjusts the target price from $140 to $160.
Jefferies analyst Tycho Peterson maintains with a buy rating, and adjusts the target price from $142 to $182.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and maintains the target price at $175.
BTIG analyst Mark Massaro maintains with a buy rating, and adjusts the target price from $150 to $185.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The reassessment of estimates for Natera, taking into account the Q3 results along with the revised outlook for 2024 and preliminary commentary on 2025 from the management discussion, supports the view that the stock's significant multiple is well warranted. This is due to several factors that are expected to contribute to both near-term and long-term upside in estimates, positioning the stock as a high-conviction selection.
Natera delivered another robust quarterly performance, according to an analyst. The company is achieving impressive results across various business aspects, such as volume, selling price, margin, and cash burn, with potential for continued enhancement through 2025. The company is considered one of the premier entities within the diagnostics sector.
Natera's Q3 results were exceptionally strong, as evidenced by the continuous improvement in its fundamentals. The company is channeling its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
Natera recorded an impressive quarter with sales, margins, and cash flow that significantly exceeded expectations.
Natera's third quarter revenue and gross margins exceeded estimates, signaling a robust business momentum. This includes a significant 60% year-over-year growth in Signatera clinical volume and noteworthy gains in the women's health sector.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
